Managing Refractory/Relapsed Hodgkin Lymphoma in Brazil | Oncotarget
Channel: Oncotarget
Date: 2023-12-19

Oncotarget #published this #trending review on December 12, 2023 in Volume 14, entitled, “Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability" by researchers from Hospital Universitário de Brasília-Universidade de Brasília/Ebserh, Brasília, DF, Brazil; Hospital DF Star, Oncologia D’Or, Rede D’Or, Brasília, DF, Brazil; Hospital A Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil; Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil; Clínica Hematológica/Grupo Oncoclinicas, Belo Horizonte, MG, Brazil; Universidade Federal da Bahia, Salvador, BA, Brazil; Instituto D'Or de Pesquisa e Ensino, IDOR, BA, Brazil; Universidade Estadual do Pará, Belém, PA, Brazil; Universidade Federal de São Paulo, São Paulo, SP, Brazil; Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil.
#cancer #chemotherapy #brazil #drugtherapy #hodgkinslymphoma #chl #research #review #cancerresearch #oncology #openaccess #openscience #peerreview #journal #publication #publishing #meded  #oncotargetshort #video 

DOI - https://doi.org/10.18632/oncotarget.28541

Correspondence to - Flávia Dias Xavier - flavia.xavier@unb.br

Abstract

Classic Hodgkin lymphoma (CHL), which accounts for 90–95% of all cases of Hodgkin lymphoma, is the most frequent cancer in adolescents and the most frequent lymphoma in adolescents and young adults. Despite progressive improvements over past decades and the general sensitivity of CHL to frontline chemotherapy, approximately 10–15% of patients have refractory disease that either does not respond to such therapy or progresses after an initial partial response. In patients with refractory or relapsed disease, standard treatment until recently consisted mainly of salvage chemotherapy, in many cases followed by high-dose chemotherapy and autologous stem-cell transplantation. However, improved understanding of the pathobiology of CHL, coupled with the introduction of novel agents, has markedly changed the treatment landscape in the past decade. Although refractory or relapsed CHL continues to be challenging, the therapeutic landscape is undergoing profound changes brought about by novel agents, particularly brentuximab vedotin and immunotherapy. In this review, we discuss the most salient treatment options for adult patients with refractory or relapsed CHL, with a special focus on the Brazilian healthcare setting, which is constrained by inherent characteristics of this system. In the attempt to balance efficacy, safety and tolerability, practicing physicians must rely on clinical trials and on results from real-world studies, and use their own point of view and experience, as well as patient characteristics and previous therapy, to make treatment decisions for refractory or relapsed CHL.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28541

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, brentuximab vedotin, drug therapy, hodgkin lymphoma, nivolumab, pembrolizumab

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957